AGF Management Ltd. trimmed its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 6.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,175,844 shares of the biopharmaceutical company's stock after selling 87,667 shares during the period. AGF Management Ltd.'s holdings in Pfizer were worth $31,195,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. State Street Corp boosted its holdings in shares of Pfizer by 1.2% during the 3rd quarter. State Street Corp now owns 290,460,600 shares of the biopharmaceutical company's stock valued at $8,405,930,000 after buying an additional 3,405,539 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Pfizer by 19.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock worth $4,124,330,000 after purchasing an additional 25,315,159 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Pfizer by 1.6% during the third quarter. Geode Capital Management LLC now owns 117,666,245 shares of the biopharmaceutical company's stock valued at $3,392,342,000 after purchasing an additional 1,855,419 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Pfizer by 22.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company's stock worth $1,101,713,000 after buying an additional 6,977,587 shares during the last quarter. Finally, Van ECK Associates Corp lifted its stake in shares of Pfizer by 28.5% in the fourth quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company's stock worth $564,739,000 after buying an additional 4,726,549 shares in the last quarter. Institutional investors own 68.36% of the company's stock.
Pfizer stock traded down $0.27 during trading on Wednesday, reaching $25.73. The company had a trading volume of 37,256,893 shares, compared to its average volume of 40,132,152. The firm's 50-day simple moving average is $26.29 and its 200 day simple moving average is $27.19. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $145.79 billion, a price-to-earnings ratio of 18.24, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61.
Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business's quarterly revenue was up 24.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.10 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, March 7th. Stockholders of record on Friday, January 24th were paid a $0.43 dividend. The ex-dividend date was Friday, January 24th. This is a boost from Pfizer's previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.69%. Pfizer's dividend payout ratio is 121.99%.
In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the business's stock in a transaction on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.06% of the company's stock.
Several analysts have commented on PFE shares. UBS Group cut their target price on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 8th. Bank of America reiterated a "neutral" rating and issued a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. Wolfe Research began coverage on shares of Pfizer in a research note on Friday, November 15th. They set an "underperform" rating and a $25.00 target price on the stock. Truist Financial reduced their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, December 18th. Finally, Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $31.92.
Check Out Our Latest Stock Report on Pfizer
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.